<生产厂家价格>

N-甲基吡咯烷酮(NMP)

N-甲基吡咯烷酮(NMP)用途

N-Methylpyrrolidone (1-Methyl-2-pyrrolidinone) 是一种五元环酰胺,是一种有机极性溶剂。N-Methylpyrrolidone 广泛用于粘合剂,油漆,燃料和药品的生产。

N-甲基吡咯烷酮(NMP)名称

[ CAS 号 ]:
872-50-4

[ 中文名 ]:
N-甲基吡咯烷酮

[ 英文名 ]:
N-Methylpyrrolidone

[中文别名 ]:

[英文别名 ]:

Methylpyrrolidone
N-Methyl-g-butyrolactone
N-methyl-α-pyrrolidone
N-methyl-2-pyridone-5-carboxamide
1-methyl-2-oxo-pyrrolidine
1-Methyl-2-pyrrolidone
MFCD00003193
N-methyl-pyrrolidin-2-one
N-methyl-pyrrolidinone
METHYLPYRROLIDINONE

N-甲基吡咯烷酮(NMP)生物活性

[ 描述 ]:

N-Methylpyrrolidone (1-Methyl-2-pyrrolidinone) 是一种五元环酰胺,是一种有机极性溶剂。N-Methylpyrrolidone 广泛用于粘合剂,油漆,燃料和药品的生产。

[ 相关类别 ]:

研究领域 >> 其他

信号通路 >> 其他 >> 其他

[参考文献]

[1]. Jing Wang, et al. Nitrate stimulation of N-Methylpyrrolidone biodegradation by Paracoccus pantotrophus: Metabolite mechanism and Genomic characterization. Bioresour Technol. 2019 Dec;294:122185.

[2]. Claudia Julieta Solís-González, et al. Novel Metabolic Pathway for N-Methylpyrrolidone Degradation in Alicycliphilus sp. Strain BQ1. Appl Environ Microbiol. 2017 Dec 15;84(1):e02136-17.

N-甲基吡咯烷酮(NMP)物理化学性质

[ 密度 ]:
1.0±0.1 g/cm3

[ 沸点 ]:
202.0±0.0 °C at 760 mmHg

[ 熔点 ]:
−24 °C(lit.)

[ 分子式 ]:
C₅H₉NO

[ 分子量 ]:
99.131

[ 闪点 ]:
86.1±0.0 °C

[ 精确质量 ]:
99.068413

[ PSA ]:
20.31000

[ LogP ]:
-0.40

[ 外观性状 ]:
无色或淡黄色液体,带有一种胺的气味

[ 蒸汽密度 ]:
3.4 (vs air)

[ 蒸汽压 ]:
0.3±0.4 mmHg at 25°C

[ 折射率 ]:
1.470

[ 储存条件 ]:
包装完整、轻装轻放,库房通风、远离明火、高温、与氧化剂分开存放

[ 稳定性 ]:
Stable, but decomposes upon exposure to light. Combustible. Incompatible with strong oxidizing agents, strong acids, reducing agents, bases.

[ 水溶解性 ]:
>=10 g/100 mL at 20 ºC

N-甲基吡咯烷酮(NMP)MSDS

N-甲基吡咯烷酮(NMP)毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UY5790000

CHEMICAL NAME :: 2-Pyrrolidinone, 1-methyl-

CAS REGISTRY NUMBER :: 872-50-4

LAST UPDATED :: 199806

DATA ITEMS CITED :: 36

MOLECULAR FORMULA :: C5-H9-N-O

MOLECULAR WEIGHT :: 99.15

WISWESSER LINE NOTATION :: T5NVTJ A

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: Standard Draize test

ROUTE OF EXPOSURE :: Administration into the eye

SPECIES OBSERVED :: Rodent - rabbit

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3914 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2472 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: >2 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 80500 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 7 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 5130 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 3050 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 54500 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 63300 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Administration onto the skin

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 8 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 30240 mg/kg/28D-C

TOXIC EFFECTS :: Behavioral - food intake (animal) Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 33750 mg/kg/90D-I

TOXIC EFFECTS :: Behavioral - muscle weakness

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 400 mg/m3/6H/4W-I

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - acute pulmonary edema Blood - changes in leukocyte (WBC) count Related to Chronic Data - death

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 100 ppm/6H/2Y-I

TOXIC EFFECTS :: Kidney, Ureter, Bladder - other changes in urine composition

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 423 mg/m3/6H/4W-I

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration - dyspnea

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 33600 mg/kg/28D-C

TOXIC EFFECTS :: Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Related to Chronic Data - death

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 9700 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :: TCLo - Lowest published toxic concentration

ROUTE OF EXPOSURE :: Inhalation

DOSE :: 150 ppm/6H

SEX/DURATION :: female 7-20 day(s) after conception

TOXIC EFFECTS :: Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - delayed effects

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Inhalation

DOSE :: 116 ppm/6H

SEX/DURATION :: multigenerations

TOXIC EFFECTS :: Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Administration onto the skin

DOSE :: 7500 mg/kg

SEX/DURATION :: female 6-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 166 mg/kg

SEX/DURATION :: female 9 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 12825 mg/kg

SEX/DURATION :: female 11-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

DOSE :: 7625 mg/kg

SEX/DURATION :: female 11-15 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

MUTATION DATA

TYPE OF TEST :: Sex chromosome loss and nondisjunction

TEST SYSTEM :: Yeast - Saccharomyces cerevisiae

DOSE/DURATION :: 154 mmol/L

REFERENCE :: EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 11,31,1988 *** OCCUPATIONAL EXPOSURE LIMITS *** OEL-DENMARK:TWA 100 ppm (400 mg/m3) JAN 1993 OEL-GERMANY:TWA 100 ppm (400 mg/m3) JAN 1993 OEL-THE NETHERLANDS:TWA 100 ppm (400 mg/m3) JAN 1993 OEL-RUSSIA:STEL 100 mg/m3 JAN 1993 OEL-SWITZERLAND:TWA 200 ppm (400 mg/m3) JAN 1993 OEL-UNITED KINGDOM:TWA 100 ppm (400 mg/m3) JAN 1993 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - M1569 No. of Facilities: 2458 (estimated) No. of Industries: 30 No. of Occupations: 43 No. of Employees: 25255 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - M1569 No. of Facilities: 3902 (estimated) No. of Industries: 63 No. of Occupations: 73 No. of Employees: 85169 (estimated) No. of Female Employees: 23478 (estimated)

N-甲基吡咯烷酮(NMP)安全信息

[ 符号 ]:

GHS07, GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H315-H319-H335-H360D

[ 警示性声明 ]:
P201-P305 + P351 + P338-P308 + P313

[ 个人防护装备 ]:
Eyeshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter

[ 危害码 (欧洲) ]:
Xi:Irritant

[ 风险声明 (欧洲) ]:
R36/38

[ 安全声明 (欧洲) ]:
S41

[ 危险品运输编码 ]:
UN 1268 3/PG 3

[ WGK德国 ]:
1

[ RTECS号 ]:
UY5790000

[ 海关编码 ]:
2933990090

N-甲基吡咯烷酮(NMP)合成路线

N-甲基吡咯烷酮(NMP)上下游产品

N-甲基吡咯烷酮(NMP)上游产品

N-甲基吡咯烷酮(NMP)下游产品

N-甲基吡咯烷酮(NMP)制备

1.由γ-丁内酯与甲胺反应而得。反应第一步是γ-丁内酯与甲胺生成4-羟基-N-甲基丁酰胺，第二步是进而脱水生成N-甲基吡咯烷酮。两步反应可按排在管式反应器中连续进行，γ-丁内酯与甲胺的摩尔比为1：1.15，压力约6MPa，温度为250℃。反应完成后，经浓缩、减压蒸馏而得成品。收率90%。如果采用釜式反就器生产，甲胺用量为理论量的1.5-2.5倍，举实验室制备为例。在500ml压热器中，加入2molγ-丁内酯和4摩尔液体甲胺，密闭加热，于280℃保温4h。冷却后放出过量的甲胺，蒸馏，收集201-202℃馏分，约得产品180g，收率约90%。原料消耗（kg/g）γ-丁内酯 980甲胺（40%）860

精制方法：将N-甲基吡咯烷酮与苯共沸蒸馏或加分子筛放置数日以除去水分，然后用柱高100cm，填有玻璃螺旋的蒸馏柱进行减压蒸馏，收集中间馏分。

2.γ-丁内酯与甲胺反应，反应完毕后冷却，去除过量的甲胺和水使产物浓缩，再经减压蒸馏即可。

N-甲基吡咯烷酮(NMP)海关

[ 海关编码 ]: 2933790090

[ 中文概述 ]:
2933790090 其他内酰胺. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:9.0% 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0%

N-甲基吡咯烷酮(NMP)文献

Safety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles.

AAPS J. 17(1) , 256-67, (2015)

Carbohydrate functionalization of nanoparticles allows for targeting of C-type lectin receptors. This family of pattern recognition receptors expressed on innate immune cells, such as macrophages and ...

Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity.

Int. J. Nanomedicine 10 , 229-43, (2015)

H5N1 avian influenza is a significant global concern with the potential to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative for pandemic vaccines compared to...

High-rate aluminium yolk-shell nanoparticle anode for Li-ion battery with long cycle life and ultrahigh capacity.

Nat. Commun. 6 , 7872, (2015)

Alloy-type anodes such as silicon and tin are gaining popularity in rechargeable Li-ion batteries, but their rate/cycling capabilities should be improved. Here by making yolk-shell nanocomposite of al...

更多文献